Mentions
Extended reach
Total likes
Video views
AI synopsis
Several discussions emphasize the high prognostic value of ctDNA testing, citing statistics such as the 88.2% sensitivity and the median lead time of 10 months before recurrence detection, which demonstrates both clinical interest and perceived impact. The tone and language, including terms like 'intriguing' and references to ongoing significant studies, highlight strong engagement and belief in the potential transformative impact of this research.
Most discussions acknowledge the significant prognostic value of ctDNA testing, citing studies like the EBLIS study and emphasizing the importance of serial monitoring.
Posts show high interest by referencing ongoing studies, potential clinical applications, and the technology's relevance for breast cancer management.
Discussions include specific details like study design, recurrence rates, and potential treatment implications, indicating active engagement.
The collective tone suggests that this research could substantially influence future breast cancer diagnostics and patient management strategies.
EBLIS study: 156 pts with eBC followed for a median of 6.5y with Signatera testing Q6M. 30/34 pts that recurred had a + ctDNA, with median lead time of 10 mo. 5/122 pts w/o recurrence had false + ctDNA. Intriguing, though benefits still remain unclear. https://t.co/YBels0p9dF https://t.co/QXdxna4uxG
術後ctDNA評価には強い予後予測価値があるという乳がんの長期フォローアップによる臨床研究報告。 論文を読んで頂けるとすぐにわかりますが、RFS、OSともに ctDNAが＋と-でカプランマイヤーが明確に分かれています。 https://t.co/WnlHrwcjkv @JCOPO_ASCO #breast #liquidbiopsy @isliquidbiopsy
Despite advancements, a lot to improve in ctDNA breast cancer https://t.co/VCXqbTZptb
RT @PTarantinoMD: EBLIS study: 156 pts with eBC followed for a median of 6.5y with Signatera testing Q6M. 30/34 pts that recurred had a + c…
RT @PTarantinoMD: EBLIS study: 156 pts with eBC followed for a median of 6.5y with Signatera testing Q6M. 30/34 pts that recurred had a + c…
RT @PTarantinoMD: EBLIS study: 156 pts with eBC followed for a median of 6.5y with Signatera testing Q6M. 30/34 pts that recurred had a + c…
This episode summarizes a study demonstrating that serial postoperative circulating tumor DNA assessment has strong prognostic value during long-term follow-up in breast cancer patients. Circulating tumor DNA shed into…
Huge.
Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer | JCO Precision Oncology https://t.co/fjjnlRpQpR
術後ctDNA評価には強い予後予測価値があるという乳がんの長期フォローアップによる臨床研究報告。 論文を読んで頂けるとすぐにわかりますが、RFS、OSともに ctDNAが＋と-でカプランマイヤーが明確に分かれています。 https://t.co/WnlHrwcjkv @JCOPO_ASCO #breast #liquidbiopsy @isliquidbiopsy
RT @PTarantinoMD: EBLIS study: 156 pts with eBC followed for a median of 6.5y with Signatera testing Q6M. 30/34 pts that recurred had a + c…
RT @PTarantinoMD: EBLIS study: 156 pts with eBC followed for a median of 6.5y with Signatera testing Q6M. 30/34 pts that recurred had a + c…
For select cases with HR+ disease, decisions about treatment management might require serial monitoring despite the ctDNA-positive result. https://t.co/ycAQahQlPh #breastcancer #ctDNA #liquidbiopsies
RT @PTarantinoMD: EBLIS study: 156 pts with eBC followed for a median of 6.5y with Signatera testing Q6M. 30/34 pts that recurred had a + c…
RT @PTarantinoMD: EBLIS study: 156 pts with eBC followed for a median of 6.5y with Signatera testing Q6M. 30/34 pts that recurred had a + c…
RT @PTarantinoMD: EBLIS study: 156 pts with eBC followed for a median of 6.5y with Signatera testing Q6M. 30/34 pts that recurred had a + c…
RT @PTarantinoMD: EBLIS study: 156 pts with eBC followed for a median of 6.5y with Signatera testing Q6M. 30/34 pts that recurred had a + c…
RT @PTarantinoMD: EBLIS study: 156 pts with eBC followed for a median of 6.5y with Signatera testing Q6M. 30/34 pts that recurred had a + c…
RT @PTarantinoMD: EBLIS study: 156 pts with eBC followed for a median of 6.5y with Signatera testing Q6M. 30/34 pts that recurred had a + c…
RT @PTarantinoMD: EBLIS study: 156 pts with eBC followed for a median of 6.5y with Signatera testing Q6M. 30/34 pts that recurred had a + c…
RT @PTarantinoMD: EBLIS study: 156 pts with eBC followed for a median of 6.5y with Signatera testing Q6M. 30/34 pts that recurred had a + c…
RT @PTarantinoMD: EBLIS study: 156 pts with eBC followed for a median of 6.5y with Signatera testing Q6M. 30/34 pts that recurred had a + c…
RT @PTarantinoMD: EBLIS study: 156 pts with eBC followed for a median of 6.5y with Signatera testing Q6M. 30/34 pts that recurred had a + c…
RT @PTarantinoMD: EBLIS study: 156 pts with eBC followed for a median of 6.5y with Signatera testing Q6M. 30/34 pts that recurred had a + c…
Despite advancements, a lot to improve in ctDNA breast cancer https://t.co/VCXqbTZptb
RT @PTarantinoMD: EBLIS study: 156 pts with eBC followed for a median of 6.5y with Signatera testing Q6M. 30/34 pts that recurred had a + c…
RT @PTarantinoMD: EBLIS study: 156 pts with eBC followed for a median of 6.5y with Signatera testing Q6M. 30/34 pts that recurred had a + c…
RT @PTarantinoMD: EBLIS study: 156 pts with eBC followed for a median of 6.5y with Signatera testing Q6M. 30/34 pts that recurred had a + c…
RT @PTarantinoMD: EBLIS study: 156 pts with eBC followed for a median of 6.5y with Signatera testing Q6M. 30/34 pts that recurred had a + c…
Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer | JCO Precision Oncology https://t.co/KuruRaaGvu
RT @PTarantinoMD: EBLIS study: 156 pts with eBC followed for a median of 6.5y with Signatera testing Q6M. 30/34 pts that recurred had a + c…
RT @PTarantinoMD: EBLIS study: 156 pts with eBC followed for a median of 6.5y with Signatera testing Q6M. 30/34 pts that recurred had a + c…
RT @PTarantinoMD: EBLIS study: 156 pts with eBC followed for a median of 6.5y with Signatera testing Q6M. 30/34 pts that recurred had a + c…
EBLIS study: 156 pts with eBC followed for a median of 6.5y with Signatera testing Q6M. 30/34 pts that recurred had a + ctDNA, with median lead time of 10 mo. 5/122 pts w/o recurrence had false + ctDNA. Intriguing, though benefits still remain unclear. https://t.co/YBels0p9dF https://t.co/QXdxna4uxG